IDEAYA Biosciences announced IDE101 as a new development candidate designed to treat tumors with CDKN2A deficiency, common in 10-15% of solid tumors including 70% of pancreatic cancers. IDE101 is a first-in-class dual cyclin-dependent kinase inhibitor showing promising preclinical activity alone and combined with RAS and PRMT5 inhibitors. The company plans to file an Investigational New Drug (IND) application with the FDA in the first half of 2027 after completing ongoing preclinical studies. IDEAYA aims to improve treatment efficacy by targeting tumor suppressor loss alongside oncogenic drivers in these cancers.
IDEAYA Biosciences' new development candidate IDE101 is introduced amid a Health sector where 71 of 150 US stocks rose and 77 fell on the day. For readers following Health stocks, here is Pluang's market snapshot as of Nov 16, 2026 00:01 WIB: HNGE traded at USD 115.39 with a 1-day change of -4.63% and a typical hold time of 12 days; RXRX was at USD 3.19, down 4.35%, with a typical hold time of 23 days and Pluang order activity showing 0% Sell / 100% Buy; BNGO stood at USD 1.00, down 3.85%, with a typical hold time of 52 days.
Alpha Tau Medical announced interim results from its U.S. trial of Alpha DaRT therapy for recurrent glioblastoma, showing all eight treated patients are alive with a median follow-up of 6.9 months and no median survival reached. Among six patients as...
A security breach redirected the computing power of about 64,000 Bitcoin mining rigs, totaling roughly 13 exahashes per second, to a single attacker-controlled mining pool called OCEAN. While Bitcoin's protocol and consensus rules remained intact, th...
Shiba Inu (SHIB) dropped below $0.000004 for the first time in 260 weeks on the Kraken exchange, marking its lowest weekly close since late 2021. This break of a long-standing support level signals potential further downside, with key levels to watch...
Bitcoin's price fell below the $65,000 mark to $64,928 on Binance's spot market at 2:27 p.m. ET Sunday, dropping $105 from its price 15 minutes earlier despite a 0.40% increase over the previous hour. This dip below the key $65,000 threshold highligh...
Bitcoin's price fell about 11% below its 200-day moving average, with the Mayer Multiple dropping to 0.88, a level seen annually but not necessarily a buy signal. Historically, after such dips, Bitcoin often experiences a further median decline of 15...
